Catalyst Event
Johnson & Johnson (JNJ) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
3/18/2026, 12:00:00 AM
The U.S. FDA approved Icotyde (icotrokinra) on March 18, 2026, the first targeted oral peptide for treating moderate-to-severe plaque psoriasis. Analysts forecast potential peak annual sales of over $5 billion forecasted. This major approval is expected to have a high market impact.
Korean Translation
2026년 3월 18일, 미국 FDA는 중등도-중증 판상 건선 치료를 위한 최초의 경구용 펩타이드 약물인 아이코타이드(이코트로킨라)를 승인함. 분석가들은 연간 최대 매출이 50억 달러를 넘을 것으로 전망됨. 이 주요 승인은 높은 시장 영향력을 미칠 것으로 예상됨.
Related Recent Events
Murphy Oil Corp (MUR) · Earnings Release
The company is expected to release its Q1 2026 earnings results on or around May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Sysco Corporation (SYY) · Earnings Release
Sysco's Q3 2026 earnings release is expected on or around May 5, 2026, based on past reporting schedules. Analysts forecast an EPS of $0.95. High importance is estimated due to historical price volatility following earnings. This is scheduled.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
The FDA has set a PDUFA target action date of April 28, 2026, for its review of the New Drug Application for doravirine/islatravir, an investigational HIV treatment. Approval typically impacts price by 5-10%, scheduled.
4/28/2026, 12:00:00 AM
United Parcel Service Inc (UPS) · Earnings Release
UPS Q1 2026 earnings release and conference call scheduled.
4/28/2026, 12:00:00 AM
Coca-Cola Co (The) (KO) · Earnings Release
First quarter 2026 earnings release on April 27, 2026, for which low importance is estimated due to typical market reaction to quarterly results, is scheduled.
4/27/2026, 12:00:00 AM